Listed

Beam Therapeutics Inc.: Form 10-Q for the period ended Sep 30, 2020

Filed with the SEC on Nov 10, 2020 and accepted by EDGAR at Nov 10, 2020, 06:49 ET.

Share

Sections

The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.

Figures reported in this filing

Standardized line items from the XBRL in this filing, for the period ended 2020-09-30. Comparative periods it repeats are left out.

Figures reported in this filing
Line itemPeriodValueXBRL concept
Research and development3 months2020-07-01 to 2020-09-30$29.8mus-gaap:ResearchAndDevelopmentExpense
Research and development9 months2020-01-01 to 2020-09-30$70.7mus-gaap:ResearchAndDevelopmentExpense
Operating income3 months2020-07-01 to 2020-09-30−$37.3mus-gaap:OperatingIncomeLoss
Operating income9 months2020-01-01 to 2020-09-30−$92.0mus-gaap:OperatingIncomeLoss
Net income3 months2020-07-01 to 2020-09-30−$34.5mus-gaap:NetIncomeLoss
Net income9 months2020-01-01 to 2020-09-30−$99.1mus-gaap:NetIncomeLoss
Operating cash flow9 months2020-01-01 to 2020-09-30−$71.4mus-gaap:NetCashProvidedByUsedInOperatingActivities
Capital expenditure9 months2020-01-01 to 2020-09-30$8.2mus-gaap:PaymentsToAcquirePropertyPlantAndEquipment
Cash and equivalentsAt period end2020-09-30$137.9mus-gaap:CashAndCashEquivalentsAtCarryingValue
Current assetsAt period end2020-09-30$208.7mus-gaap:AssetsCurrent
Total assetsAt period end2020-09-30$278.3mus-gaap:Assets
Current liabilitiesAt period end2020-09-30$47.5mus-gaap:LiabilitiesCurrent
Total liabilitiesAt period end2020-09-30$78.2mus-gaap:Liabilities
Shareholders' equityAt period end2020-09-30$200.1mus-gaap:StockholdersEquity

Source: SEC EDGAR, the filing index for accession 0001564590-20-052723. Last ingested by Listed: Nov 14, 2026, 12:58 ET. Listed shows no prices and gives no investment advice.